Hikma Pharmaceuticals (LON:HIK) Shares Pass Above Two Hundred Day Moving Average – Time to Sell?

Hikma Pharmaceuticals PLC (LON:HIK) shares crossed above its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of GBX 1,647.04 and traded as high as GBX 1,661. Hikma Pharmaceuticals shares last traded at GBX 1,652, with a volume of 833,808 shares traded.

Analyst Upgrades and Downgrades

Several brokerages have recently issued reports on HIK. JPMorgan Chase & Co. reduced their price target on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set an “overweight” rating for the company in a report on Friday, November 7th. Peel Hunt reissued a “buy” rating and set a GBX 2,170 target price on shares of Hikma Pharmaceuticals in a research note on Friday, November 7th. Berenberg Bank restated a “buy” rating and issued a GBX 2,300 target price on shares of Hikma Pharmaceuticals in a research report on Thursday, January 22nd. Deutsche Bank Aktiengesellschaft dropped their price target on shares of Hikma Pharmaceuticals from GBX 2,500 to GBX 2,400 and set a “buy” rating on the stock in a research note on Friday, January 9th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a GBX 2,360 price objective on shares of Hikma Pharmaceuticals in a research report on Friday, November 7th. Five investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of GBX 2,326.

Hikma Pharmaceuticals Stock Down 15.3%

The company has a debt-to-equity ratio of 55.82, a current ratio of 1.66 and a quick ratio of 1.27. The firm has a market capitalization of £3.10 billion, a P/E ratio of 8.38, a PEG ratio of 2.38 and a beta of 0.41. The firm’s fifty day moving average price is GBX 1,560.84 and its 200-day moving average price is GBX 1,647.04.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 800+ (as of Feb 2025) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.